T. ROWE PRICE ASSOCIATES, INC. just provided an update on share ownership of Corvus Pharmaceuticals, Inc.

T. ROWE PRICE ASSOCIATES, INC. just filed a "Statement of acquisition of beneficial ownership", which is also known as a 13G. In the filing, it appears as though T. ROWE PRICE ASSOCIATES, INC. claims to own 647,174 shares. This represents 2.2% of Corvus Pharmaceuticals, Inc..

Please note that typos are common in SEC filings. Please verify the information reported above before acting on it.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback